This is a single-group, within-subject, double-blind, double-dummy, placebo and
active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol)
would enhance analgesia, subjective reports, and cognitive performance when compared to the
FDA-approved opioid hydromorphone (Dilaudid).